Skip to content
Recruiting

Host Genome Methylation: a Screening Tool in Anal Cancer Detection

About this study

In January 2023, the first recommendations for anal cancer screening were issued by the French National Society of Coloproctology (SNFCP). These were the world's first national recommendations for anal cancer screening for at-risk patients, not limited to people living with HIV. They are based on screening for papillomavirus type 16 (HPV16) as the first line of defence, followed by reflex cytology in the event of a positive HPV16 smear and a proctological examination. In the event of abnormal cytology or proctological examination, high-resolution anoscopy (HRA) should be performed, but access to it is limited by the number of proctologists with the expertise to carry out this examination and the cost of the equipment. The development of biological markers could enable only patients at high risk of high-grade dysplasia/anal cancer to be referred for HRA. As part of the AIN3 cohort, we demonstrated that the markers ZNF582 and ASCL1, studied on anal smears taken when patients were included in the cohort, showed a significantly higher level of methylation in patients who subsequently progressed to anal cancer. The aim of this project is to test, in real-life conditions, the contribution of these methylation markers in the triage of asymptomatic patients eligible for anal cancer screening according to the SNFCP guidelines (MSM over 30 years of age living with HIV, women with a history of vulvar lesions or vulvar, women patients who have had a solid organ transplant for more than 10 years and extension to men patients who have had a solid organ transplant for more than 10 years).

Condition
Anal Cancer
Tested
Anal self-sampling (smear), HPV questionnaire
Sponsor
Assistance Publique - Hôpitaux de Paris

Who can join

Age
18 years and older
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 13

  • Minimum age: 18 years
  • Study condition: Anal Cancer
  • Adults (age ≥ 18 years)
  • Eligible for anal cancer screening according to the SNFCP guidelines (with extension to men who have received solid organ transplants for more than 10 years):
  • MSM (men who have sex with men) aged over 30 living with HIV
  • Patients who have received a solid organ transplant for more than 10 years
  • Women with a history of vulvar lesions or vulvar cancer
  • Non-inclusion Criteria:
  • Proctological follow-up for a current high-grade anal lesion or cancer
  • Pregnant or breastfeeding women
  • Subject deprived of liberty or under legal protection
  • Non-affiliation with social security system
  • Refusal to participate expressed by the patient

Exclusion 1

  • \) Refusal of anal self-sampling on inclusion

Where

9 sites, 3 recruiting

Gynecology and Obstetrics Department Bichat-Claude Bernard Hospital

Paris, Île-de-France Region, France

Recruiting

Infectious and Tropical Diseases Department Bichat-Claude Bernard Hospital

Paris, Île-de-France Region, France

Recruiting

Dermatology Department

Paris, Île-de-France Region, France

Recruiting

Cardiovascular Surgery and Transplantation Department Bichat-Claude Bernard Hospital

Paris, Île-de-France Region, France

Hepato-Gastroenterology, Digestive Oncology, and Proctology Department Bichat-Claude Bernard Hospital

Paris, Île-de-France Region, France

Nephrology Department Bichat-Claude Bernard Hospital

Paris, Île-de-France Region, France

and 3 more sites on ClinicalTrials.gov

Contact

Potential match only. Final eligibility is determined by the study team.